Even more important, cemiplimab displays its antitumor activity regardless of PD-L1 status, tumor histology, performance status, and the number of prior lines, thus demonstrating a broadened activity compared to pembrolizumab (Table 1) [22••]. This evidence concerns the gene CD274 and neoplasm.